Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Celgene Corp (NASDAQ:CELG)

116.78
Delayed Data
As of May 26
 +0.04 / +0.03%
Today’s Change
94.42
Today|||52-Week Range
127.64
+0.89%
Year-to-Date
Charting the Biotechs
May 26 / TheStreet.com - Paid Partner Content
Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint
May 23 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene
May 25 / Zacks.com - Paid Partner Content
Celgene Stock Rises Premarket on Positive Late-Stage Test Results for Multiple Sclero...
May 22 / TheStreet.com - Paid Partner Content
Patience Is a Virtue for Biotech Investing
May 24 / TheStreet.com - Paid Partner Content
Celgene's (CELG) Revlimid Looks Solid on Label Expansion
May 16 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data
May 24 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close116.74
Today’s open116.93
Day’s range116.35 - 117.18
Volume2,557,459
Average volume (3 months)3,705,909
Market cap$91.2B
Dividend yield--
Data as of 3:59pm ET, 05/26/2017

Growth & Valuation

Earnings growth (last year)+28.35%
Earnings growth (this year)+22.68%
Earnings growth (next 5 years)+20.02%
Revenue growth (last year)+22.70%
P/E ratio43.9
Price/Sales8.51
Price/Book13.77

Competitors

 Today’s
change
Today’s
% change
BMYBristol-Myers Squibb-0.42-0.77%
LLYEli Lilly and Co-0.29-0.37%
AZNAstraZeneca-0.49-1.43%
ABBVAbbVie-0.26-0.39%
Data as of 4:02pm ET, 05/26/2017

Financials

Next reporting dateJuly 27, 2017
EPS forecast (this quarter)$1.78
Annual revenue (last year)$10.9B
Annual profit (last year)$2.0B
Net profit margin18.30%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Mark J. Alles
President &
Chief Operating Officer
Scott Andrew Smith
Corporate headquarters
Summit, New Jersey

Forecasts